Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …

Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal
damage as well as its quantification is a critical step for patients. Blood-based serum …

Importance There is a lack of validated biomarkers for disability progression independent of
relapse activity (PIRA) in multiple sclerosis (MS). Objective To determine how serum glial …

Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …

In the management of neurological diseases, the identification and quantification of axonal
damage could allow for the improvement of diagnostic accuracy and prognostic assessment …

Objective Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the
cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood …

Objective To assess the value of blood neurofilament light chain (NfL) as a biomarker of
recent, ongoing, and future disease activity and tissue damage and its utility to monitor …

Interest in neurofilaments has risen sharply in recent years with recognition of their potential
as biomarkers of brain injury or neurodegeneration in CSF and blood. This is in the context …

Neuro-axonal injury is a key factor in the development of permanent disability in multiple
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …